Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with -$8.8 million as the latest value for Q2 2025.
- Quarterly Net Income towards Common Stockholders fell 86.55% to -$8.8 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$35.7 million through Jun 2025, down 59.69% year-over-year, with the annual reading at -$37.9 million for FY2025, 69.5% down from the prior year.
- Net Income towards Common Stockholders hit -$8.8 million in Q2 2025 for Benitec Biopharma, up from -$14.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.5 million in Q1 2022 to a low of -$14.5 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$5.7 million across 5 years, with a median of -$4.8 million in 2021.
- Biggest five-year swings in Net Income towards Common Stockholders: rose 23.03% in 2024 and later tumbled 238.89% in 2025.
- Year by year, Net Income towards Common Stockholders stood at -$4.8 million in 2021, then dropped by 15.95% to -$5.6 million in 2022, then dropped by 20.98% to -$6.8 million in 2023, then dropped by 8.22% to -$7.4 million in 2024, then decreased by 19.68% to -$8.8 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for BNTC at -$8.8 million in Q2 2025, -$14.5 million in Q1 2025, and -$7.4 million in Q4 2024.